title: Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.
abstract: BACKGROUND
  The 2015 Coffey-Holden Prostate Cancer Academy Meeting, themed: "Multidisciplinary Intervention of Early, Lethal Metastatic Prostate Cancer," was held in La Jolla, California from June 25 to 28, 2015.
  
  
  METHODS
  The Prostate Cancer Foundation (PCF) sponsors an annual, invitation-only, action-tank-structured meeting on a critical topic concerning lethal prostate cancer. The 2015 meeting was attended by 71 basic, translational, and clinical investigators who discussed the current state of the field, major unmet needs, and ideas for addressing earlier diagnosis and treatment of men with lethal prostate cancer for the purpose of extending lives and making progress toward a cure.
  
  
  RESULTS
  The questions addressed at the meeting included: cellular and molecular mechanisms of tumorigenesis, evaluating, and targeting the microenvironment in the primary tumor, advancing biomarkers for clinical integration, new molecular imaging technologies, clinical trials, and clinical trial design in localized high-risk and oligometastatic settings, targeting the primary tumor in advanced disease, and instituting multi-modal care of high risk and oligometastatic patients.
  
  
  CONCLUSIONS
  This article highlights the current status, greatest unmet needs, and anticipated field changes that were discussed at the meeting toward the goal of optimizing earlier interventions to potentiate cures in high-risk and oligometastatic prostate cancer patients.
authors.affiliation: Prostate Cancer Foundation, Santa Monica, California.
authors.forename: Andrea K
authors.initials: AK
authors.lastname: Miyahira
authors.affiliation: University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin.|Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Lang
authors.affiliation: Department of Radiation Oncology, Sidney Kimmel Medical Center, Thomas Jefferson University, Philadelphia, Pennsylvania.|Department of Cancer Biology, Sidney Kimmel Medical Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors.forename: Robert B
authors.initials: RB
authors.lastname: Den
authors.affiliation: Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.|Jonsson Comprehensive Cancer Center, Los Angeles,, California.|Greater Los Angeles VA Healthcare System, Los Angeles, California.
authors.forename: Isla P
authors.initials: IP
authors.lastname: Garraway
authors.affiliation: Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland.|Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland.
authors.forename: Tamara L
authors.initials: TL
authors.lastname: Lotan
authors.affiliation: Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland.|Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland.|Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland.
authors.forename: Ashley E
authors.initials: AE
authors.lastname: Ross
authors.affiliation: Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California.
authors.forename: Tanya
authors.initials: T
authors.lastname: Stoyanova
authors.affiliation: University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin.|Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
authors.forename: Steve Y
authors.initials: SY
authors.lastname: Cho
authors.affiliation: Prostate Cancer Foundation, Santa Monica, California.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Simons
authors.affiliation: Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland.|Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland.|Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland.
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Pienta
authors.affiliation: Prostate Cancer Foundation, Santa Monica, California.
authors.forename: Howard R
authors.initials: HR
authors.lastname: Soule
mesh_terms: D000047:Academies and Institutes / Q000639:trends; D002140:California; D003226:Congresses as Topic / Q000639:trends; D061345:Early Medical Intervention / Q000379:methods* / Q000639:trends; D006801:Humans; D007400:Interprofessional Relations; D008297:Male; D010348:Patient Care Team / Q000639:trends; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D058028:Research Report
keywords: biomarkers; diagnosis; molecular imaging; oligometastatic; therapeutics